作者: Stefani Spranger , Riyue Bao , Thomas F. Gajewski
DOI: 10.1038/NATURE14404
关键词:
摘要: Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches,. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs,,). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8+ T-cell …